Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$1.6b

Vera Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Marshall Fordyce

Chief executive officer

US$5.6m

Total compensation

CEO salary percentage10.9%
CEO tenure9yrs
CEO ownership0.5%
Management average tenure2.3yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?

Mar 14
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?

Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?

Mar 07

Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late

Dec 22

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jul 22

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Jul 05
Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Jan 25

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Sep 06

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Aug 10

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16
Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25
We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Marshall Fordyce's remuneration changed compared to Vera Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$175m

Dec 31 2024US$6mUS$616k

-US$152m

Sep 30 2024n/an/a

-US$134m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$3mUS$586k

-US$96m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$107m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$551k

-US$89m

Sep 30 2022n/an/a

-US$73m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$45m

Dec 31 2021US$1mUS$479k

-US$33m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$360k

-US$53m

Compensation vs Market: Marshall's total compensation ($USD5.65M) is about average for companies of similar size in the US market ($USD6.11M).

Compensation vs Earnings: Marshall's compensation has increased whilst the company is unprofitable.

CEO

Marshall Fordyce (49 yo)

9yrs

Tenure

US$5,648,201

Compensation

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...

Leadership Team

NamePositionTenureCompensationOwnership
Marshall Fordyce
Founder9yrsUS$5.65m0.45%
$ 7.3m
Jason Carter
Chief Legal Officerless than a yearUS$5.83mno data
Robert Brenner
Chief Medical Officer1.3yrsUS$4.46m0.0019%
$ 30.6k
Sean Grant
Chief Financial Officer3.8yrsUS$1.76m0.071%
$ 1.2m
David Johnson
Chief Opearating Officerless than a yearno datano data
Joseph Young
Senior VP of Finance & Chief Accounting Officer4yrsno data0.046%
$ 748.8k
Allen Ebens
Executive Vice President of Research1.3yrsUS$397.02kno data
Debra Charlesworth
Vice President of Corporate Communicationsless than a yearno datano data
Emma Haywood
Vice President of Marketingless than a yearno datano data
Kelly Rauber
Senior Vice President of Human Resources3.3yrsno datano data
Tom Doan
Executive Vice President of Development Operations5.2yrsno datano data
Lauren Frenz
Chief Business Officer7.8yrsno datano data

2.3yrs

Average Tenure

50yo

Average Age

Experienced Management: VERA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marshall Fordyce
Founder9yrsUS$5.65m0.45%
$ 7.3m
Maha Katabi
Independent Director4.6yrsUS$436.59k0%
$ 0
Michael Morrissey
Independent Chairman of the Board3yrsUS$471.59k0%
$ 0
Patrick Gerald Enright
Independent Director4.6yrsUS$438.59k0%
$ 0
Beth Seidenberg
Independent Director8.9yrsUS$436.59k0.21%
$ 3.5m
Scott William Morrison
Independent Director5.1yrsUS$446.59k0%
$ 0
Andrew Cheng
Independent Director8yrsUS$437.59k0.027%
$ 446.4k
Christy Oliger
Independent Directorless than a yearUS$775.40k0.0047%
$ 76.2k
Kimball Hall
Independent Director3.4yrsUS$432.59k0%
$ 0

4.6yrs

Average Tenure

57yo

Average Age

Experienced Board: VERA's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 06:09
End of Day Share Price 2025/05/06 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vera Therapeutics, Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Liisa BaykoEvercore ISI
Paul ChoiGoldman Sachs